Cabaletta Bio, Inc. (CABA)
NASDAQ: CABA · Real-Time Price · USD
1.710
+0.380 (28.57%)
At close: Aug 13, 2025, 4:00 PM
1.700
-0.010 (-0.58%)
Pre-market: Aug 14, 2025, 6:24 AM EDT
ASLAN Pharmaceuticals Employees
As of December 31, 2024, Cabaletta Bio had 164 total employees, including 161 full-time and 3 part-time employees. The number of employees increased by 61 or 59.22% compared to the previous year.
Employees
164
Change (1Y)
61
Growth (1Y)
59.22%
Revenue / Employee
n/a
Profits / Employee
-$879,793
Market Cap
156.41M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 164 | 61 | 59.22% |
Dec 31, 2023 | 103 | 43 | 71.67% |
Dec 31, 2022 | 60 | 6 | 11.11% |
Dec 31, 2021 | 54 | 20 | 58.82% |
Dec 31, 2020 | 34 | 12 | 54.55% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CABA News
- 6 days ago - Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 14 days ago - What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? - Benzinga
- 2 months ago - Cabaletta Bio Announces Pricing of Public Offering of Securities - GlobeNewsWire
- 2 months ago - Cabaletta Bio: Sector Headwinds And Funding Issues - Seeking Alpha
- 2 months ago - Cabaletta Bio Announces Proposed Public Offering of Securities - GlobeNewsWire
- 2 months ago - Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress - GlobeNewsWire
- 2 months ago - Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts - GlobeNewsWire